Palatin Technologies, Inc. (PTN)

NYSEAMERICAN: PTN · IEX Real-Time Price · USD
3.607
-0.013 (-0.36%)
Feb 27, 2024, 9:32 AM EST - Market open
-0.36%
Market Cap 51.96M
Revenue (ttm) 7.10M
Net Income (ttm) -31.59M
Shares Out 16.14M
EPS (ttm) -2.61
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 139,216
Open 3.650
Previous Close 3.620
Day's Range 3.600 - 3.700
52-Week Range 1.430 - 5.650
Beta 1.12
Analysts Strong Buy
Price Target 70.00 (+1,840.67%)
Earnings Date Feb 14, 2024

About PTN

Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that is in Phase 2 clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide m... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Oct 28, 1993
Employees 34
Stock Exchange NYSEAMERICAN
Ticker Symbol PTN
Full Company Profile

Financial Performance

In 2023, PTN's revenue was $4.85 million, an increase of 230.53% compared to the previous year's $1.47 million. Losses were -$27.54 million, -23.91% less than in 2022.

Financial Statements

Analyst Forecast

According to one analyst, the rating for PTN stock is "Strong Buy" and the 12-month stock price forecast is $70.0.

Price Target
$70.0
(1,840.67% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Palatin Reports Second Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update

Palatin's Focus is Solely on the Development of its Melanocortin Receptor (MCR) System Pipeline PL9643 MELODY-1 Pivotal Phase 3 Study in Dry Eye Disease (DED) – Topline Data Expected in February Oral ...

12 days ago - PRNewsWire

Palatin to Report Second Quarter Fiscal Year 2024 Results; Teleconference and Webcast to be held on February 15, 2024

CRANBURY, N.J. , Feb. 9, 2024 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) will announce its second quarter fiscal year 2024 operating results on Thursday, February 15, 2024, before...

18 days ago - PRNewsWire

Palatin Announces Database Lock for PL9643 MELODY-1 Pivotal Phase 3 Clinical Trial in Patients with Dry Eye Disease (DED)

Top-Line Results Expected in February CRANBURY, N.J. , Feb. 5, 2024 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines bas...

22 days ago - PRNewsWire

Palatin Announces Closing of $10 Million Registered Direct Offering

CRANBURY, N.J. , Feb. 1, 2024 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) ("Palatin" or the "Company"), a biopharmaceutical company developing first-in-class medicines based on mol...

25 days ago - PRNewsWire

Palatin Announces $10 Million Registered Direct Offering

CRANBURY, N.J. , Jan. 30, 2024 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) ("Palatin" or the "Company"), a biopharmaceutical company developing first-in-class medicines based on mo...

4 weeks ago - PRNewsWire

Palatin Provides Corporate Update and Highlights Strategic Priorities for Calendar Year 2024

Dry Eye Disease (DED): PL9643 MELODY-1 Phase 3 Study Data Base Lock 2H January 2024 Topline Data Readout Expected Early 1Q Calendar Year 2024 Ulcerative Colitis (UC): Oral PL8177 Phase 2 Clinical Stud...

7 weeks ago - PRNewsWire

Cosette Pharmaceuticals Acquires Vyleesi® (Bremelanotide Injection) from Palatin Technologies Inc.

BRIDGEWATER, N.J.--(BUSINESS WIRE)-- #HSDD--Cosette Pharmaceuticals Acquires Vyleesi® (Bremelanotide Injection) from Palatin Technologies Inc.

7 weeks ago - Business Wire

Palatin Completes Sale of Vyleesi® to Cosette Pharmaceuticals for up to $171 Million

Palatin to receive $12 million upfront, plus sales-based milestones of up to $159 million Palatin's focus is solely on its development and clinical pipeline based on the melanocortin receptor system C...

2 months ago - PRNewsWire

Palatin Receives Notice of Acceptance of the Listing Standards Compliance Plan from NYSE American

CRANBURY, N.J. , Dec. 18, 2023 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the act...

2 months ago - PRNewsWire

Palatin Reports First Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update

Enrollment Complete in Phase 3 PL9643 MELODY-1 Study in Dry Eye Disease (DED) 570 Patients Enrolled Topline Data Currently Expected Late 4Q Calendar Year 2023 Phase 2 Clinical Study of Oral PL8177 in ...

3 months ago - PRNewsWire

Palatin to Report First Quarter Fiscal Year 2024 Results; Teleconference and Webcast to be held on November 14, 2023

CRANBURY, N.J. , Nov. 9, 2023 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) will announce its first quarter fiscal year 2024 operating results on Tuesday, November 14, 2023, before t...

3 months ago - PRNewsWire

Palatin Announces Closing of $5 Million Registered Direct Offering

CRANBURY, N.J. , Oct. 24, 2023 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) ("Palatin" or the "Company"), a biopharmaceutical company developing first-in-class medicines based on mo...

4 months ago - PRNewsWire

Palatin Announces $5 Million Registered Direct Offering

CRANBURY, N.J. , Oct. 23, 2023 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) ("Palatin" or the "Company"), a biopharmaceutical company developing first-in-class medicines based on mo...

4 months ago - PRNewsWire

Palatin Announces Preliminary Quarter Ended September 30, 2023 Vyleesi® Product Revenue Results

7 Consecutive Quarters of Double-Digit Growth in Product Revenue and Prescriptions Dispensed $4.6 million in Gross Product Revenue 11% growth over prior quarter; 100% growth over comparable quarter la...

4 months ago - PRNewsWire

Palatin Announces Positive Preclinical Data Showing Synergistic Weight Loss; Initiating Clinical Study of Melanocortin 4 Receptor Agonist + GLP-1 in Obese Patients

Positive data with Palatin's melanocortin-4 receptor (MC4R) agonist plus glucagon like peptide-1 (GLP-1) presented at the Peptide Therapeutics Symposium GLP-1 & MC4R agonist co-administration data sho...

4 months ago - PRNewsWire

Palatin Presents Data at the United European Gastroenterology Week 2023 Conference On PL8177 Ulcerative Colitis Treatment

Data demonstrates oral PL8177 causes diseased colons to move to a healthier state Provides further support for ongoing oral PL8177 Phase 2 ulcerative colitis study CRANBURY, N.J. , Oct. 16, 2023 /PRNe...

4 months ago - PRNewsWire

Palatin Receives Notice of Non-Compliance from NYSE American

Palatin to Deliver Plan of Compliance to NYSE American CRANBURY, N.J. , Oct. 13, 2023 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-c...

4 months ago - PRNewsWire

Palatin Reports Fourth Quarter and Fiscal Year Ended 2023 Financial Results and Provides Corporate Update

Enrollment in Phase 3 PL9643  MELODY-1 Study in Dry Eye Disease (DED) is Complete with 570 Patients Enrolled Topline Data Expected Late 4Q Calendar Year 2023 Interim Analysis of Initial 120 Patients S...

5 months ago - PRNewsWire

Palatin to Report Fourth Quarter and Fiscal Year End 2023 Results; Teleconference and Webcast to be held on September 28, 2023

CRANBURY, N.J. , Sept. 22, 2023 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) will announce its fourth quarter and fiscal year end 2023 operating results on Thursday, September 28, 2...

5 months ago - PRNewsWire

Palatin to Present at the H.C. Wainwright 25th Annual Global Investment Conference

CRANBURY, N.J. , Sept. 7, 2023 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the act...

6 months ago - PRNewsWire

Palatin Completes Enrollment in Phase 3 MELODY-1 Study of PL9643 For the Treatment of Patients with Dry Eye Disease

Topline data currently expected late 4Q calendar 2023 Interim analysis of first 120 patients demonstrated: Excellent safety and tolerability product profile  Potential for PL9643 to address multiple s...

6 months ago - PRNewsWire

Palatin Initiates Clinical Program for Bremelanotide Co-Formulated with a PDE5i for the Treatment of ED in Patients Non-Responsive to PDE5i Treatment

~30-40% of ED patients do not respond to PDE5i treatment Published clinical data and mechanisms of action support clinical study of bremelanotide in combination with a PDE5i Successfully co-formulated...

7 months ago - PRNewsWire

Palatin's Vyleesi® Licensee Fosun Pharma Reports First Commercial Sale in China and South Korean Licensee Kwangdong Pharmaceuticals Completes Enrollment in Phase 3 Clinical Study

First prescription dispensed in Chinese Hainan Province 93% of patients enrolled completed the Phase 3 trial in premenopausal patients with Hypoactive Sexual Desire Disorder (HSDD) in South Korea Data...

7 months ago - PRNewsWire

Palatin Announces Direct-to-Consumer Telehealth Partnership with UpScriptHealth™ for Vyleesi®

Partnership will increase hypoactive sexual desire disorder (HSDD) awareness and expand access to Vyleesi via UpScriptHealth's Women's Health Platform CRANBURY, N.J. , Aug. 7, 2023 /PRNewswire/ -- Pal...

7 months ago - PRNewsWire

Palatin to Participate in Canaccord Genuity's 43rd Annual Growth Conference

CRANBURY, N.J. , Aug. 4, 2023 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the acti...

7 months ago - PRNewsWire